肾功能下降对头孢他啶药代动力学的影响。
Effect of decreased renal function on the pharmacokinetics of ceftazidime.
作者信息
Ackerman B H, Ross J, Tofte R W, Rotschafer J C
出版信息
Antimicrob Agents Chemother. 1984 Jun;25(6):785-6. doi: 10.1128/AAC.25.6.785.
Abstract
The pharmacokinetics of ceftazidime after a 1-g bolus dose were studied in 11 subjects, with creatinine clearances ranging from 113 to 6 ml/min. Concentrations of ceftazidime in serum were determined by microbiological assay. These data were fitted to a two-compartment open model, and pharmacokinetic parameters were calculated. Correlation of ceftazidime clearance with creatinine clearance was excellent (r = 0.99).
摘要
在11名肌酐清除率范围为113至6 ml/min的受试者中研究了1克头孢他啶大剂量推注后的药代动力学。通过微生物测定法测定血清中头孢他啶的浓度。将这些数据拟合到二室开放模型，并计算药代动力学参数。头孢他啶清除率与肌酐清除率的相关性极佳（r = 0.99）。
相似文献
1
Effect of decreased renal function on the pharmacokinetics of ceftazidime.肾功能下降对头孢他啶药代动力学的影响。
Antimicrob Agents Chemother. 1984 Jun;25(6):785-6. doi: 10.1128/AAC.25.6.785.
2
Pharmacokinetics of ceftazidime in patients with renal insufficiency.头孢他啶在肾功能不全患者中的药代动力学。
Antimicrob Agents Chemother. 1984 Feb;25(2):201-4. doi: 10.1128/AAC.25.2.201.
3
Pharmacokinetics of ceftazidime in normal and uremic subjects.头孢他啶在正常人和尿毒症患者体内的药代动力学。
Antimicrob Agents Chemother. 1984 May;25(5):638-42. doi: 10.1128/AAC.25.5.638.
4
Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.头孢美唑在正常受试者及肾功能不全患者中的药代动力学。
Antimicrob Agents Chemother. 1980 Sep;18(3):386-9. doi: 10.1128/AAC.18.3.386.
5
Pharmacokinetics of ceftazidime in normal and impaired renal function.
Arzneimittelforschung. 1984;34(1):72-6.
6
Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.头孢替坦在正常受试者及肾功能受损患者中的药代动力学。
Antimicrob Agents Chemother. 1983 Jan;23(1):31-5. doi: 10.1128/AAC.23.1.31.
7
Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency.头孢呋辛的血浆和肾脏清除率测定及其在肾功能不全患者中的药代动力学
J Antimicrob Chemother. 1979 May;5(3):281-92. doi: 10.1093/jac/5.3.281.
8
Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function.头孢沙定在健康志愿者和肾功能受损患者中的药代动力学。
Chemotherapy. 1981;27(3):149-54. doi: 10.1159/000237971.
9
Pharmacokinetics of cefamandole in patients with renal impairment.头孢孟多在肾功能损害患者中的药代动力学。
Antimicrob Agents Chemother. 1979 Feb;15(2):161-4. doi: 10.1128/AAC.15.2.161.
10
The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.头孢他啶在肾功能受损且同时接受速尿治疗患者中的药代动力学。
Eur J Clin Pharmacol. 1988;35(3):273-9. doi: 10.1007/BF00558265.
引用本文的文献
1
Application of Physiologically Based Pharmacokinetic Model to Delineate the Impact of Aging and Renal Impairment on Ceftazidime Clearance.基于生理的药代动力学模型在描述衰老和肾功能损害对头孢他啶清除率影响中的应用。
Antibiotics (Basel). 2024 Sep 9;13(9):862. doi: 10.3390/antibiotics13090862.
2
Pharmacokinetic/Pharmacodynamic Target Attainment of Ceftazidime in Adult Patients on General Wards with Different Degrees of Renal Function: A Prospective Observational Bicenter Cohort Study.不同肾功能程度普通病房成年患者中头孢他啶的药代动力学/药效学目标达成情况：一项前瞻性观察性双中心队列研究
Antibiotics (Basel). 2023 Feb 25;12(3):469. doi: 10.3390/antibiotics12030469.
3
Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.阿米卡星与头孢他啶药代动力学参数的相关性
Clin Pharmacokinet. 2007;46(10):859-66. doi: 10.2165/00003088-200746100-00004.
4
Population pharmacokinetics of continuous infusion ceftazidime.
Clin Pharmacokinet. 1999 Oct;37(4):343-50. doi: 10.2165/00003088-199937040-00005.
5
Clinical pharmacokinetics of newer cephalosporins.新型头孢菌素的临床药代动力学
Clin Pharmacokinet. 1995 May;28(5):361-84. doi: 10.2165/00003088-199528050-00003.
6
Clinical pharmacokinetics of the third generation cephalosporins.第三代头孢菌素的临床药代动力学
Clin Pharmacokinet. 1985 Mar-Apr;10(2):101-43. doi: 10.2165/00003088-198510020-00001.
7
Dosage adjustment for ceftazidime in patients with impaired renal function.
Eur J Clin Pharmacol. 1986;30(5):597-605. doi: 10.1007/BF00542421.
8
Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.头孢他啶在年轻、健康及老年急性病男性中的比较药代动力学。
Eur J Clin Pharmacol. 1988;34(2):179-86. doi: 10.1007/BF00614556.
9
Clinical pharmacokinetics of antibiotics in patients with impaired renal function.肾功能受损患者抗生素的临床药代动力学
Clin Pharmacokinet. 1992 Mar;22(3):169-210. doi: 10.2165/00003088-199222030-00002.
本文引用的文献
1
Beta-lactamase-producing Bacteroides species in the oral cavity in relation to penicillin therapy.口腔中产β-内酰胺酶拟杆菌属与青霉素治疗的关系。
J Antimicrob Chemother. 1981 Sep;8(3):225-9. doi: 10.1093/jac/8.3.225.
2
Comparative pharmacokinetics of ceftazidime and moxalactam.头孢他啶和拉氧头孢的比较药代动力学
Antimicrob Agents Chemother. 1982 Aug;22(2):237-41. doi: 10.1128/AAC.22.2.237.
3
Ceftazidime: pharmacokinetics in patients and effects on the renal function.
J Antimicrob Chemother. 1982 Sep;10(3):199-206. doi: 10.1093/jac/10.3.199.
4
Bactericidal and bacteriolytic activity of serum against gram-negative bacteria.血清对革兰氏阴性菌的杀菌和溶菌活性。
Microbiol Rev. 1983 Mar;47(1):46-83. doi: 10.1128/mr.47.1.46-83.1983.
5
Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.将人体视为具有单室性质进行药代动力学分析时存在的缺点。
J Pharm Sci. 1968 Jan;57(1):117-23. doi: 10.1002/jps.2600570123.
6
Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.通过静脉输注后获得的输注后血药浓度曲线评估药代动力学常数。
J Pharm Sci. 1970 Jan;59(1):53-5. doi: 10.1002/jps.2600590107.
Zotero 插件